BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 23, 2006
 |  BioCentury  |  Product Development

Shrinking AMD lesions

GenVec Inc. believes that its pigment epithelium-derived factor gene therapy for wet age-related macular degeneration could reverse AMD lesions based on its putative mechanism and anecdotal clinical observations from a Phase I trial in late-stage patients.

In an open-label, U.S. Phase I trial in 28 patients with advanced neovascular AMD, patients received a single intravitreous injection of an adenoviral vector carrying the human PEDF gene. Although statistical significance was not reached, the researchers reported last week in Human Gene Therapy that patients receiving higher doses of the gene therapy appeared to fare better.

At three...

Read the full 467 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >